Lonquex

RSS

lipegfilgrastim

Authorised
This medicine is authorised for use in the European Union.

Overview

Lonquex is a medicine that contains the active substance lipegfilgrastim. It is used to reduce the duration of neutropenia (low levels of neutrophils, a type of white blood cell) and the occurrence of febrile neutropenia (neutropenia with fever) in patients with cancer aged 2 years and older receiving cytotoxic chemotherapy.

Cytotoxic chemotherapy (medicines that kill fast growing cells) commonly causes neutropenia because as well as killing cancer cells, it also kills other fast-growing cells such as neutrophils, leaving the patient at risk of infections.

Lonquex is not used in patients receiving chemotherapy for chronic myeloid leukaemia (a cancer of the white blood cells) and myelodysplastic syndromes (a disease that can develop into a leukaemia).

This EPAR was last updated on 12/12/2022

Authorisation details

Product details
Name
Lonquex
Agency product number
EMEA/H/C/002556
Active substance
lipegfilgrastim
International non-proprietary name (INN) or common name
lipegfilgrastim
Therapeutic area (MeSH)
Neutropenia
Anatomical therapeutic chemical (ATC) code
L03AA14
Publication details
Marketing-authorisation holder
Teva B.V.
Revision
24
Date of issue of marketing authorisation valid throughout the European Union
25/07/2013
Contact address

Swensweg 5
2031GA Haarlem
The Netherlands

Product information

17/10/2022 Lonquex - EMEA/H/C/002556 - IAIN/0075

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.

 

Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

  • Immunostimulants

  • Colony stimulating factors

Therapeutic indication

Lonquex is indicated in adults and in children 2 years of age and older for reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes).

Assessment history

Changes since initial authorisation of medicine

Related content

How useful was this page?

Add your rating
Average
1 rating
1 rating